- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Primary insulin-like growth factor 1 deficiency (Primary IGFD)
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1623KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 410KB)
Mecasermin – November 2021
Mecasermin: Solution for injection 40 mg in 4 mL vial; Increlex®
Last updated
18 March 2022